文献速递浆细胞疾病造血干细胞移植与细胞治疗

脐带血来源自然杀伤细胞联合自体干细胞移植治疗多发性骨髓瘤的I期研究

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
PubMed 文献 · Br J Haematol · 2017-03-14

该I期研究纳入12例接受大剂量化疗和自体造血干细胞移植的多发性骨髓瘤患者,在四个脐带血来源自然杀伤细胞剂量水平(5×10^6、1×10^7、5×10^7、1×10^8个细胞/kg)各入组3例,联合来那度胺和马法兰。未观察到输注毒性和移植物抗宿主病,10例患者最佳疗效达至少非常好的部分缓解,其中8例达近完全缓解或更好;中位随访21个月,4例进展或复发,2例死亡。

要点

  • 脐带血来源自然杀伤细胞联合自体移植未观察到输注毒性和移植物抗宿主病。
  • 12例中10例最佳疗效达至少非常好的部分缓解,其中8例达近完全缓解或更好。
  • 中位随访21个月,4例进展或复发,其中2例死亡;6例患者体内检测到活化表型脐带血来源自然杀伤细胞。

核心结论

  • 这些数据支持进一步开发这种新型细胞疗法。

研究设计与样本

  • 首次人体I期研究,纳入12例接受大剂量化疗和自体造血干细胞移植的多发性骨髓瘤患者。
  • 四个脐带血来源自然杀伤细胞剂量水平各入组3例:5×10^6、1×10^7、5×10^7和1×10^8个细胞/kg。
  • 治疗方案为来那度胺10 mg第-8至-2天,马法兰200 mg/m2第-7天,脐带血来源自然杀伤细胞第-5天,自体造血干细胞移植第0天。

主要发现

  • 12例中10例有高危染色体改变或复发/进展病史。
  • 未观察到输注毒性,未发生移植物抗宿主病。
  • 1例因自体移植物质量差而植入失败,使用备份自体移植物挽救。
  • 总体10例最佳疗效达至少非常好的部分缓解,其中8例达近完全缓解或更好。
  • 中位随访21个月,4例进展或复发,其中2例死亡;6例患者体内检测到活化表型(NKG2D+/NKp30+)的脐带血来源自然杀伤细胞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a disease with known immune dysregulation. Natural killer (NK) cells have shown preclinical activity in MM. We conducted a first-in-human study of umbilical cord blood-derived (CB) NK cells for MM patients undergoing high dose chemotherapy and autologous haematopoietic stem cell transplantation (auto-HCT). Patients received lenalidomide (10 mg) on days -8 to -2, melphalan 200 mg/m2 on day -7, CB-NK cells on day -5 and auto-HCT on day 0. Twelve patients were enrolled, three on each of four CB-NK cell dose levels: 5 × 106 , 1 × 107 , 5 × 107 and 1 × 108 CB-NK cells/kg. Ten patients had either high-risk chromosomal changes or a history of relapsed/progressed disease. There were no infusional toxicities and no graft-versus-host disease. One patient failed to engraft due to poor autologous graft quality and was rescued with a back-up autologous graft. Overall, 10 patients achieved at least a very good partial response as their best response, including eight with near complete response or better. With a median follow-up of 21 months, four patients have progressed or relapsed, two of whom have died. CB-NK cells were detected in vivo in six patients, with an activated phenotype (NKG2D+ /NKp30+ ). These data warrant further development of this novel cellular therapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Shah N, Li L, McCarty J, et al. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017. PMID: 28295190. doi:10.1111/bjh.14570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。